Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lutetium-177 Octreotate (PNT2003) / Lantheus, Eli Lilly
NCT02743741: Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors	Active, not recruiting	N/A	195	Canada	Lutetium-177 Octreotate, Lu-DOTATATE, [Lu-177]-DOTATATE	University Health Network, Toronto, Ozmosis Research Inc., Cancer Care Ontario, Canadian Molecular Imaging Probe Consortium	Neuroendocrine Tumors	06/26	06/26